CA-HYPERICE
15.9.2022 12:02:01 CEST | Business Wire | Press release
Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most consistent and even distribution of heat to relieve sore, stiff muscles and promote wellness. Venom Go advances the capabilities of the Venom line further with the ability to deliver heat and vibration spot treatment in more areas, such as the neck, shoulder, upper and lower back, calf and forearm. Designed with flexibility in mind, Venom Go can be utilized in more environments than ever before, with unmatched versatility and customizations, delivering instant muscle relief wherever the body needs it most. Venom 2 is the most advanced heat and massage wrap on the market and carries on the legacy built by the original Venom line, which revolutionized the traditional heating pad for consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005442/en/
"The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.” -Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. (Photo: Business Wire)
“The new Venom Go is a revolutionary product for us as it widens the application of our Venom technology and addresses the need for a powerful heat and vibration solution for spot treatment,” said Jim Huether, CEO of Hyperice. “It’s been six years since the debut of heat and vibration technology from Hyperice, we’ve now significantly enhanced the Venom user experience and added our patented HyperHeat™ technology, all while staying true to the core elements of the original product that made people fall in love with it. The Venom line is one of our fastest growing product lines, and we expect this trend to continue in the U.S. and throughout the world.”
INTRODUCING VENOM GO
The Venom Go is a heat and vibration wearable that consists of a control pod that magnetically connects to an adhesive pad and is applied directly to the skin. Venom Go pads are reusable approximately 20 to 40 times each (depending on placement on body and any sweat, lotion or oil that may be on the skin) and cover 13.5 square inches, allowing users to receive direct treatment to more areas of the body than ever before. Users can select from 3 levels of heat and 3 levels of vibration via easy to use button control on the pod. Sore and stiff muscles can now receive instant treatment, with Venom Go reaching up to 113℉ (45°C) in 90 seconds after applied to the skin - or just 20 seconds prior to being applied to the skin.
The Venom Go control pod and pad weighs a mere 0.2 lbs, and holds a battery life of up to 60 minutes on a full charge, with a standard session running for 10 minutes. The Venom Go is charged via USB connection and is TSA approved for convenient use while traveling. Utilizing Bluetooth connectivity, the Venom Go is controlled via the Hyperice App, with users having the ability to sync multiple pods to deliver tailored spot treatments across different areas of the body at once for a unique heat and vibration therapy experience.
“Recovery plays a key role in performing your best every day,” said Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. “Venom has always been a staple product in my warmup and recovery routines. Vibration and heat are both critical components in the equation. The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.”
The introduction of the Venom Go comes on the heels of the introduction of the Normatec Go (currently only available in the US), and now provides a holistic suite of products within Hyperice’s Go series (Hypersphere Mini, Hypervolt Go 2, Vyper Go, Normatec Go). Portable and mobile adaptations of each product line offer users maximum flexibility to experience the benefits of warm up and recovery technology in more places, and at more price points, than ever before.
“With the Venom Go, users will be able to experience the same benefits they have grown to know and love in the Venom line, but in many more targeted areas for relief,” added Huether. “This product is amazing for anyone with soreness, stiffness or pain in targeted areas, and furthers our mission to help as many people as possible improve their daily lives through recovery and movement.”
INTRODUCING VENOM 2
The Venom 2, which comes in versions for the back, leg and shoulder (left or right), has more-than-doubled its treatment area, increasing the overall heating surface by 111% (94 square inches), and is encased in a new silicone surface for easier cleaning. Venom 2 delivers up to a three-hour battery life on a full charge, and heats to 131℉ (55°C) in just one minute, which is four times faster than the original Venom, and six times faster than a traditional heating pad. Users will also experience a lighter version of the Venom, as the weight drops by more than 23% from the original version, now weighing just two lbs.
“Heat therapy is such a critical component of my routine, from preparing for a game and getting my shoulder loose, to treating sore muscles in my arm between practices,” said Patrick Mahomes, Hyperice Athlete-Investor and Super Bowl Champion. “From pregame, to the training facility and home, the Venom line allows me to optimize my performance. The new Venom 2 improves the experience and I know will be a popular tool in the locker room.”
“As a footballer, I need to ensure that my body is ready to endure the rigors that come with a 90-minute match,” said Erling Haaland, Hyperice Athlete-Investor and global footballer. “Heat therapy is very important in ensuring my body is properly prepared and ready to go ahead of training or kickoff, and equally important in the time between match-days. I’m always looking for ways to give myself a competitive edge, and with Venom 2’s heating time, I feel the benefits quicker than ever before, and can be ready to take the pitch faster with my body ready to go.”
Through Bluetooth® connectivity, the Venom 2 is controlled via the Hyperice App, unlocking more routines to maximize and customize time, heat and vibration while using the device.
HYPERHEAT™ TECHNOLOGY
With the launch of Venom Go and the Venom 2, Hyperice also introduces their new HyperHeat™ technology which delivers a faster, more consistent distribution of heat across a greater surface area, allowing for a more premium experience for users.
“In 2015 we were getting requests from NBA players for a product that could heat the body pregame and keep the body warm when they came out of the game. Our answer was the Venom, the first heat and vibration wearable device, released in 2017,” said Anthony Katz, Hyperice Founder. “Over the past five years, the user base for the Venom has expanded far beyond performance athletes to everyday people who use the Venom to manage pain and soreness. The Venom 2 is a complete redesign and upgrade from the original model- every aspect of the product and experience have been improved.“
The Venom Go ($149; £159; €175) and Venom 2 line ($249; £269; €299) are available in North America as well as globally across all countries and regions where Hyperice is sold. For more information, please visit hyperice.com country-specific sites.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
